New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 19, 2014
08:37 EDTELGXEndologix investors should add to positions, says Canaccord
Canaccord recommends investors add to positions in Endologix following investor meetings with management. The firm believes top line growth will accelerate in the second half of the year and that Nellix will make it one of the most compelling long-term growth stories in addition to making it an attractive takeover target. Shares are Buy rated with a $17.50 price target.
News For ELGX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 19, 2015
08:45 EDTELGXEndologix to present 'positive' Nellix clinical data at VEITH Symposium
Subscribe for More Information
07:32 EDTELGXCanaccord to hold a forum
Subscribe for More Information
November 18, 2015
16:04 EDTELGXEndologix, TriVascular announce early termination of HSR waiting period
Subscribe for More Information
10:01 EDTELGXEndologix to host investor meeting
Investor meeting to be held in New York on November 19 at 6 pm. Webcast Link
07:41 EDTELGXEndologix announces start of physician-initiated registry of Nellix EVAS System
Endologix announced the start of a physician-initiated registry of the Nellix EndoVascular Aneurysm Sealing System, or Nellix EVAS System, used with aortic branch stent grafts for the treatment of patients with complex abdominal aortic aneurysms, or AAAs. The registry, to be conducted outside of the United States, will be called the ASCEND Registry. The primary investigators are Andrew Holden, MD, Associate Professor of Radiology at Auckland Hospital; and Professor Matthew Thompson, MD, Professor of Vascular Surgery, St. Georges Vascular Institute, London. The Nellix System received CE Mark in 2013 for the treatment of patients with infrarenal AAAs. The Nellix System is an investigational device in the United States.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use